Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-Glu-urea-Lys-HBED-CC-FITC
- Development stage
- Preclinical
- Lead developer
- German Cancer Research Center
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
68Ga-Glu-urea-Lys-HBED-CC-FITC is a dual-labeled small molecule radiopharmaceutical and fluorescent probe designed for the management of prostate cancer. It is a derivative of the established PET tracer 68Ga-PSMA-11, utilizing a glutamate-urea-lysine (EuK) pharmacophore to target the Prostate-Specific Membrane Antigen (PSMA) with high affinity (IC50 of 11.14 nM). The molecule incorporates a Gallium-68 isotope via an HBED-CC chelator for preoperative positron emission tomography (PET) imaging and is conjugated to fluorescein isothiocyanate (FITC) to provide intraoperative fluorescence guidance. This hybrid approach allows for the preoperative identification of tumor lesions and subsequent real-time visual guidance during surgical resection. Preclinical studies have demonstrated high PSMA-specific internalization and significant tumor uptake, supporting its potential for improving surgical outcomes in prostate cancer patients.
- Other names
- 68Ga-PSMA-11-FITC68Ga-Glu-urea-Lys-HBED-CC-fluoresceinFITC-labeled PSMA-11 derivative
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 68Ga-Glu-urea-Lys-HBED-CC-FITC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-Glu-urea-Lys-HBED-CC-FITC.